Roquefort Therapeutics plc (LON:ROQ) Insider Stephen Paul West Purchases 2,400,000 Shares of Stock

Roquefort Therapeutics plc (LON:ROQ) insider Stephen Paul West bought 2,400,000 shares of the stock in a transaction on Friday, July 4th. The shares were acquired at an average cost of GBX 2 ($0.03) per share, for a total transaction of £48,000 ($65,332.79).

Roquefort Therapeutics Trading Up 30.1%

Shares of ROQ opened at GBX 1.60 ($0.02) on Tuesday. The firm’s fifty day moving average is GBX 1.61 and its two-hundred day moving average is GBX 2.23. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The stock has a market cap of £2.04 million, a PE ratio of -1.32 and a beta of 0.05. Roquefort Therapeutics plc has a 52-week low of GBX 1.08 ($0.01) and a 52-week high of GBX 6.78 ($0.09).

Roquefort Therapeutics (LON:ROQ) last announced its quarterly earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.